The US pharmaceutical industry is constantly changing. With tough regulatory scrutiny and emphasis on quality issues, many are asking how they can keep up and what trends they should be following in order to break through the stigma.
“With the first FDA-approved cannabis extract (Epidiolex) emerging from the stigma of recreational cannabis, the pharmaceutical industry has taken notice of the potential therapeutic uses of scheduled drugs with no currently accepted medical use,” says Jessica Rousset, COO at CURE Pharmaceutical. “Last year, the FDA fast-tracked studies evaluating the safety and effectiveness of MDMA to treat PTSD and psilocybin for the treatment of depression.”
Read the full article: US Pharma Outlook: Ten Trends to Look Out For in 2020 (CPHI)
